Michael A Kamm

List of Publications by Year
in descending order

197 papers	18,974 citations	14614 66 h-index	11899 134 g-index
199 all docs	199 docs citations	199 times ranked	13477 citing authors

#	Article	IF	Citations
1	Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. New England Journal of Medicine, 2004, 350, 876-885.	13.9	2,026
2	Prospective comparison of faecal incontinence grading systems. Gut, 1999, 44, 77-80.	6.1	1,157
3	Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004, 53, 1617-1623.	6.1	1,012
4	Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet, The, 2017, 389, 1218-1228.	6.3	908
5	Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study. Gastroenterology, 2013, 145, 158-165.e2.	0.6	633
6	A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohnâ€™s Disease. Gastroenterology, 2005, 129, 807-818.	0.6	571
7	Crohn's disease management after intestinal resection: a randomised trial. Lancet, The, 2015, 385, 1406-1417.	6.3	475
8	Mechanisms of action of probiotics: Recent advances. Inflammatory Bowel Diseases, 2009, 15, 300-310.	0.9	448
9	Randomized controlled trial of biofeedback for fecal incontinence. Gastroenterology, 2003, 125, 1320-1329.	0.6	383
10	Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis. Gastroenterology, 2007, 132, 66-75.	0.6	325
11	Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis, 2017, 11, 1180-1199.	0.6	323
12	Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut, 2015, 64, 1063-1071.	6.1	320
13	A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut, 2014, 63, 1381-1392.	6.1	317
14	Obstetric damage and faecal incontinence. Lancet, The, 1994, 344, 730-733.	6.3	313
15	Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. Gastroenterology, 2019, 156, 1440-1454.e2.	0.6	290
16	Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut, 2011, 60, 923-929.	6.1	288
17	Development of the LÃ©mann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease. Gastroenterology, 2015, 148, 52-63.e3.	0.6	257
18	Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery. Gastroenterology, 2015, 148, 938-947.e1.	0.6	241

#	Article	IF	Citations
19	Diagnosis and treatment of chronic constipation - a European perspective. Neurogastroenterology and Motility, 2011, 23, 697-710.	1.6	239
20	Sacral nerve stimulation for intractable constipation. Gut, 2010, 59, 333-340.	6.1	229
21	Bowel dysfunction: a pathogenic factor in uterovaginal prolapse and urinary stress incontinence. BJOG: an International Journal of Obstetrics and Gynaecology, 1994, 101, 147-152.	1.1	207
22	American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21â€“23, 2006. Gastroenterology, 2007, 133, 312-339.	0.6	197
23	Tegaserod for the Treatment of Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Multinational Study. American Journal of Gastroenterology, 2005, 100, 362-372.	0.2	187
24	Urbanization and the gut microbiota in health and inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 440-452.	8.2	187
25	Biofeedback provides long term benefit for patients with intractable, slow and normal transit constipation. Gut, 1998, 42, 517-521.	6.1	177
26	Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific. American Journal of Gastroenterology, 2019, 114, 107-115.	0.2	172
27	Permanent sacral nerve stimulation for treatment of idiopathic constipation. British Journal of Surgery, 2002, 89, 882-888.	0.1	168
28	Oral Bisacodyl Is Effective and Well-Tolerated in Patients With Chronic Constipation. Clinical Gastroenterology and Hepatology, 2011, 9, 577-583.	2.4	166
29	Serological Antibodies in Inflammatory Bowel Disease: A Systematic Review. Inflammatory Bowel Diseases, 2012, 18, 1340-1355.	0.9	164
30	Postoperative recurrent luminal CrohnÊ¼s Disease: A systematic review. Inflammatory Bowel Diseases, 2012, 18, 758-777.	0.9	162
31	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1381-1392.	2.4	161
32	Recent Advances in Characterizing the Gastrointestinal Microbiome in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	157
33	Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. Journal of Neurology, 1995, 242, 105-108.	1.8	149
34	Prospective Evaluation of Anti-Tumor Necrosis Factor Therapy Guided by Magnetic Resonance Imaging for CrohnÊ¼s Perineal Fistulas. American Journal of Gastroenterology, 2009, 104, 2973-2986.	0.2	145
35	Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Alimentary Pharmacology and Therapeutics, 2003, 17, 387-393.	1.9	140
36	Outcome of biofeedback for faecal incontinence. British Journal of Surgery, 2002, 86, 1159-1163.	0.1	137

#	Article	IF	Citations
37	Association between specific mucosaâ€associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: A pilot study. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 268-278.	1.4	137
38	The normal range and a simple diagram for recording whole gut transit time. International Journal of Colorectal Disease, 1992, 7, 15-17.	1.0	136
39	Fortnightly review : Faecal incontinence. BMJ: British Medical Journal, 1998, 316, 528-532.	2.4	126
40	Short-term Effects of Sacral Nerve Stimulation for IdiopathicSlow Transit Constipation. World Journal of Surgery, 2002, 26, 166-170.	0.8	124
41	Donor Recruitment for Fecal Microbiota Transplantation. Inflammatory Bowel Diseases, 2015, 21, 1600-1606.	0.9	122
42	Double-blind placebo-controlled crossover study of sacral nerve stimulation for idiopathic constipation. British Journal of Surgery, 2002, 89, 1570-1571.	0.1	115
43	Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in highâ€risk patients â€“ a POCER study analysis. Alimentary Pharmacology and Therapeutics, 2015, 42, 867-879.	1.9	115
44	Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation.. Gut, 1995, 37, 95-99.	6.1	114
45	Long-term MRI-guided combined anti-TNF-Î± and thiopurine therapy for crohnÊ¼s perianal fistulas. Inflammatory Bowel Diseases, 2012, 18, 1825-1834.	0.9	114
46	Proteus spp. as Putative Gastrointestinal Pathogens. Clinical Microbiology Reviews, 2018, 31, .	5.7	111
47	Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. Cell Host and Microbe, 2020, 27, 823-829.e3.	5.1	110
48	Prospective Assessment of Accuracy of Endoanal MR Imaging and Endosonography in Patients with Fecal Incontinence. American Journal of Roentgenology, 2000, 175, 741-745.	1.0	109
49	Response to a behavioural treatment, biofeedback, in constipated patients is associated with improved gut transit and autonomic innervation. Gut, 2001, 49, 214-219.	6.1	108
50	First Prospective, Population-Based Inflammatory Bowel Disease Incidence Study in Mainland of China. Inflammatory Bowel Diseases, 2013, 19, 1.	0.9	94
51	Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia. Gastroenterology, 2016, 150, 86-95.e3.	0.6	94
52	Endpoints for clinical trials evaluating disease modification and structural damage in adults with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 1599-1604.	0.9	93
53	Preliminary examination of the relations between disease activity, illness perceptions, coping strategies, and psychological morbidity in CrohnÊ¼s disease guided by the common sense model of illness. Inflammatory Bowel Diseases, 2011, 17, 2551-2557.	0.9	92
54	Mesalamine Did Not Prevent Recurrent Diverticulitis in Phase 3 Controlled Trials. Gastroenterology, 2014, 147, 793-802.	0.6	91

#	Article	IF	Citations
55	Lateral division of the puborectalis muscle in the management of severe constipation. British Journal of Surgery, 2005, 75, 661-663.	0.1	88
56	Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health. Inflammatory Bowel Diseases, 2010, 16, 15-22.	0.9	88
57	Systematic review with metaâ€analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Alimentary Pharmacology and Therapeutics, 2019, 49, 354-363.	1.9	87
58	Predictive Value of Impaired Evacuation at Proctography in Diagnosing Anismus. American Journal of Roentgenology, 2001, 177, 633-636.	1.0	86
59	Microbial Factors Associated with Postoperative Crohnâ€™s Disease Recurrence. Journal of Crohn's and Colitis, 2017, 11, 191-203.	0.6	86
60	Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE). Gut, 2020, 69, 83-91.	6.1	85
61	Bowel function and transit rate during the menstrual cycle.. Gut, 1989, 30, 605-608.	6.1	84
62	Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial. American Journal of Gastroenterology, 2009, 104, 1170-1179.	0.2	83
63	Visceral adiposity predicts postâ€operative Crohn's disease recurrence. Alimentary Pharmacology and Therapeutics, 2017, 45, 1255-1264.	1.9	80
64	Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Alimentary Pharmacology and Therapeutics, 2007, 25, 557-567.	1.9	79
65	Observation on the characteristics of stimulated defaecation in severe idiopathic constipation. International Journal of Colorectal Disease, 1992, 7, 197-201.	1.0	78
66	Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis. Inflammatory Bowel Diseases, 2009, 15, 1-8.	0.9	78
67	Psychological Morbidity in Women With Idiopathic Constipation. American Journal of Gastroenterology, 2000, 95, 2852-2857.	0.2	74
68	Therapeutic strategies for the management of ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 935-950.	0.9	65
69	Impact of Drug Therapy and Surgery on Quality of Life in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2015, 21, 1187-1194.	0.9	65
70	Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 129-134.	0.9	64
71	Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 890-899.	3.7	64
72	Dynamic scanning defines a colonic defect in severe idiopathic constipation.. Gut, 1988, 29, 1085-1092.	6.1	63

#	Article	IF	Citations
73	Rapid changes in epidemiology of inflammatory bowel disease. Lancet, The, 2017, 390, 2741-2742.	6.3	60
74	Management of Postoperative Crohn's Disease. American Journal of Gastroenterology, 2008, 103, 1029-1035.	0.2	59
75	Defined microbiota transplant restores Th17/RORÎ³t⁺regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21536-21545.	3.3	58
76	Elucidation of Proteus mirabilis as a Key Bacterium in Crohnâ€™s Disease Inflammation. Gastroenterology, 2021, 160, 317-330.e11.	0.6	58
77	Perianal Fistulizing Crohnâ€™s Disease: A Call to Action. Clinical Gastroenterology and Hepatology, 2008, 6, 7-10.	2.4	57
78	The complexity of drug development for irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2002, 16, 343-351.	1.9	52
79	Survey of laxative use by adults with selfâ€defined constipation in South America and Asia: a comparison of six countries. Alimentary Pharmacology and Therapeutics, 2010, 31, 274-284.	1.9	52
80	Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. Gut, 2020, 69, 801-810.	6.1	52
81	Magnetic resonance imaging of the pelvic floor in patients with obstructed defaecation. British Journal of Surgery, 1997, 84, 1555-1558.	0.1	51
82	Prospective assessment of the effect on quality of life of antiâ€tumour necrosis factor therapy for perineal Crohnâ€™s fistulas. Alimentary Pharmacology and Therapeutics, 2009, 30, 757-766.	1.9	49
83	Improving the efficacy of sacral nerve stimulation for faecal incontinence by alteration of stimulation parameters. British Journal of Surgery, 2009, 96, 778-784.	0.1	47
84	Clinical and surgical recurrence of CrohnÊ¼s disease after ileocolonic resection in a specialist unit. European Journal of Gastroenterology and Hepatology, 2009, 21, 551-557.	0.8	45
85	Rectodynamics â€" quantifying rectal evacuation. International Journal of Colorectal Disease, 1989, 4, 161-163.	1.0	43
86	Constipation and its management. BMJ: British Medical Journal, 2003, 327, 459-460.	2.4	43
87	Relations between symptom severity, illness perceptions, visceral sensitivity, coping strategies and well-being in irritable bowel syndrome guided by the common sense model of illness. Psychology, Health and Medicine, 2017, 22, 524-534.	1.3	43
88	Steroid hormone abnormalities in women with severe idiopathic constipation.. Gut, 1991, 32, 80-84.	6.1	42
89	Electrogastrography in chronic intestinal pseudoobstruction. Digestive Diseases and Sciences, 1996, 41, 1292-1297.	1.1	42
90	Non-surgical management of faecal incontinence. British Journal of Hospital Medicine, 2001, 62, 538-541.	0.3	40

#	Article	IF	Citations
91	Adalimumab sustains steroidâ€free remission after 3â€ƒyears of therapy for Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 306-317.	1.9	39
92	Addition of thiopurines can recapture response in patients with <scp>C</scp>rohn's disease who have lost response to antiâ€tumor necrosis factor monotherapy. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1595-1599.	1.4	39
93	Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Alimentary Pharmacology and Therapeutics, 2020, 52, 1551-1562.	1.9	38
94	Development and validation of a patientâ€reported disability measurement tool for patients with <scp>inflammatory bowel disease</scp>. Alimentary Pharmacology and Therapeutics, 2013, 37, 438-444.	1.9	37
95	Fecal microbiota transplantation therapy in Crohn's disease: Systematic review. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2672-2686.	1.4	35
96	The management of constipation in adults. Alimentary Pharmacology and Therapeutics, 1993, 7, 487-500.	1.9	34
97	Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 919-927.	1.4	34
98	Postoperative recurrence of Crohnâ€™s disease: impact of endoscopic monitoring and treatment stepâ€up. Colorectal Disease, 2013, 15, 187-197.	0.7	34
99	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohnâ€™s Disease. Gastroenterology, 2018, 155, 76-87.	0.6	34
100	Anorexia nervosa in gastrointestinal practice. European Journal of Gastroenterology and Hepatology, 2004, 16, 1135-1142.	0.8	33
101	Long-term outcome of sacral neuromodulation for chronic refractory constipation. Techniques in Coloproctology, 2017, 21, 277-286.	0.8	33
102	Management of idiopathic megarectum and megacolon. British Journal of Surgery, 2005, 78, 899-900.	0.1	32
103	Effect of Intestinal Resection on Quality of Life in Crohn's Disease. Journal of Crohn's and Colitis, 2015, 9, 452-462.	0.6	30
104	Exploration of Health Status, Illness Perceptions, Coping Strategies, and Psychological Morbidity in Stoma Patients. Journal of Wound, Ostomy and Continence Nursing, 2014, 41, 573-580.	0.6	28
105	Prevalence of mental health disorders in inflammatory bowel disease: an Australian outpatient cohort. Clinical and Experimental Gastroenterology, 2015, 8, 197.	1.0	28
106	Chronic pelvic pain in women - gastroenterological, gynaecological or psychological?. International Journal of Colorectal Disease, 1997, 12, 57-62.	1.0	27
107	Maintenance of remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2002, 16, 21-24.	1.9	26
108	Diet and gut microbiome in gastrointestinal disease. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 237-245.	1.4	25

#	Article	IF	Citations
109	Evaluation of the intrinsic innervation of the internal anal sphincter using electrical stimulation.. Gut, 1989, 30, 935-938.	6.1	24
110	Contribution of gastrointestinal transit and pouch characteristics in determining pouch function.. Gut, 1997, 40, 790-793.	6.1	24
111	Variants in <scp>ACTG</scp>2 underlie a substantial number of Australasian patients with primary chronic intestinal pseudoâ€obstruction. Neurogastroenterology and Motility, 2018, 30, e13371.	1.6	23
112	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2018, 12, 653-661.	0.6	22
113	Luminal microbiota related to Crohnâ€™s disease recurrence after surgery. Gut Microbes, 2020, 11, 1713-1728.	4.3	22
114	Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Alimentary Pharmacology and Therapeutics, 2021, 53, 810-820.	1.9	22
115	Comparison of Fecal Inflammatory Markers in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2016, 22, 1086-1094.	0.9	21
116	Serologic antibodies in relation to outcome in postoperative Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1195-1203.	1.4	21
117	Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. Inflammatory Bowel Diseases, 2020, 26, 93-102.	0.9	20
118	Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 318-331.	3.7	20
119	The surgical treatment of severe idiopathic constipation. International Journal of Colorectal Disease, 1987, 2, 229-235.	1.0	19
120	Practical application of anti-TNF therapy for luminal CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2011, 17, 2366-2391.	0.9	18
121	Review article: biological drugs in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2006, 24, 80-89.	1.9	17
122	925j Optimising post-operative Crohn's disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. The POCER study.. Gastroenterology, 2013, 144, S-164.	0.6	17
123	Delivery of care for functional gastrointestinal disorders: A systematic review. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 204-210.	1.4	17
124	Prevalence of disordered eating in adults with gastrointestinal disorders: A systematic review. Neurogastroenterology and Motility, 2022, 34, e14278.	1.6	17
125	Outcome of hospital outpatient treatment of functional gastrointestinal disorders. Internal Medicine Journal, 2019, 49, 225-231.	0.5	16
126	Magnetic resonance enterography for predicting the clinical course of Crohn's disease strictures. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 980-987.	1.4	15

#	Article	IF	Citations
127	Long-Term Outcome of Multidisciplinary Versus Standard Gastroenterologist Care for Functional Gastrointestinal Disorders: A Randomized Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 2102-2111.e9.	2.4	14
128	1161 Adalimumab Prevents Post-Operative Crohn's Disease Recurrence, and is Superior to Thiopurines: Early Results From the POCER Study. Gastroenterology, 2012, 142, S-212.	0.6	13
129	Endoscopic Prediction of Crohnâ€™s Disease Postoperative Recurrence. Inflammatory Bowel Diseases, 2022, 28, 680-688.	0.9	13
130	Clinical Case: Chronic Constipation. Gastroenterology, 2006, 131, 233-239.	0.6	12
131	Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease. Intestinal Research, 2016, 14, 152.	1.0	12
132	Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy. Gut, 2021, 70, 2210-2211.	6.1	12
133	Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 344-361.	1.4	11
134	Novel strain-level resolution of Crohnâ€™s disease mucosa-associated microbiota via an ex vivo combination of microbe culture and metagenomic sequencing. ISME Journal, 2021, 15, 3326-3338.	4.4	11
135	The gut microbiota: cause and cure of gut diseases. Medical Journal of Australia, 2018, 209, 312-317.	0.8	10
136	Non-invasive Serological Monitoring for Crohnâ€™s Disease Postoperative Recurrence. Journal of Crohn's and Colitis, 2022, 16, 1797-1807.	0.6	10
137	Investigation of faecal incontinence. British Journal of Hospital Medicine, 2001, 62, 533-537.	0.3	9
138	Chronic active disease and maintaining remission in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2004, 20, 102-105.	1.9	9
139	Systematic review: efficacy of escalated maintenance antiâ€tumour necrosis factor therapy in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 249-266.	1.9	9
140	Cost-effectiveness of Crohnâ€™s disease post-operative care. World Journal of Gastroenterology, 2016, 22, 3860.	1.4	9
141	Outcome of behavioural treatment for idiopathic chronic constipation. Internal Medicine Journal, 2014, 44, 858-864.	0.5	8
142	312 The First Validated Post-Operative Endoscopic Crohns Disease Index: The POCER Index. Identification of Key Endoscopic Prognostic Factors. Gastroenterology, 2016, 150, S72.	0.6	8
143	Gut-Directed Pelvic Floor Behavioral Treatment for Fecal Incontinence and Constipation in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 620-626.	0.9	8
144	A radiopaque marker technique for measuring gastrointestinal transit in subjects with an ileostomy. Digestive Diseases and Sciences, 1996, 41, 2302-2306.	1.1	7

#	Article	IF	Citations
145	Intestinal pseudo-obstruction. Gut, 2000, 47, 84iv-84.	6.1	7
146	Simple waterâ€based tacrolimus enemas for refractory proctitis. JGH Open, 2020, 4, 561-564.	0.7	7
147	Processed food affects the gut microbiota: The revolution has started. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 6-7.	1.4	7
148	Primary and Secondary Disorders of Gut Muscle and Nerve. Scandinavian Journal of Gastroenterology, 1996, 31, 91-93.	0.6	6
149	Pharmacological modulation of gut mucosal and large vessel blood flow. Alimentary Pharmacology and Therapeutics, 2007, 25, 693-702.	1.9	6
150	Drug management of ulcerative colitis.. BMJ: British Medical Journal, 1992, 305, 35-38.	2.4	6
151	The gut microbiota and gut disease. Internal Medicine Journal, 2021, 51, 1594-1604.	0.5	6
152	Idiopathic Constipation: Any Movement?. Scandinavian Journal of Gastroenterology, 1992, 27, 106-109.	0.6	5
153	Debate: Should Mesalamine Be Used in CrohnÊ¼s Disease?. Inflammatory Bowel Diseases, 2005, 11, 616-617.	0.9	5
154	P837 The common food additives sodium sulfite and polysorbate 80 have a profound inhibitory effect on the commensal, anti-inflammatory bacterium Faecalibacterium prausnitzii: the ENIGMA study. Journal of Crohn's and Colitis, 2019, 13, S542-S543.	0.6	5
155	Systematic review: Pelvic floor muscle training for functional bowel symptoms in inflammatory bowel disease. JGH Open, 2019, 3, 494-507.	0.7	5
156	Determinants of longâ€term function and general wellâ€being in patients with an ileoanal pouch. JGH Open, 2021, 5, 91-98.	0.7	5
157	Why the enteric nervous system is important to clinicians. Gut, 2000, 47, 8iv-9.	6.1	4
158	Slow transit constipation: more than one disease?. Gut, 2002, 51, 610-610.	6.1	4
159	W1096 Results from An Open-Label Extension of CHARM: Steroid-Free Remission in Patients with Crohn's Disease Who Received Adalimumab Therapy for At Least 3 Years. Gastroenterology, 2009, 136, A-653.	0.6	4
160	Longâ€term outcomes of perianal fistulizing Crohn's disease in the biologic era. JGH Open, 2021, 5, 235-241.	0.7	4
161	Early surgical intervention in ulcerative colitis. Gut, 2004, 53, 308-309.	6.1	3
162	Mesenteric dendritic cells from germ-free mice cause less T-cell stimulation but still induce Î±4Î²7 integrin. Microbial Ecology in Health and Disease, 2007, 19, 171-183.	3.8	3

#	Article	IF	Citations
163	The small intestine and colon. European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 362-3.	2.2	2
164	Su1994 â€“ The Common Food Additives Sodium Sulfite and Polysorbate 80 Have a Profound Inhibatory Effect on the Commensal, Anti-Inflammatory Bacterium Faecalibacterium Prausnitzii. the Enigma Study. Gastroenterology, 2019, 156, S-684-S-685.	0.6	2
165	261 â€“ Proteus is a Key Candidate in the Pathogenesis of Crohn's Disease: Mucosa, Stool Genomics and Functional Analysis: the Enigma Study. Gastroenterology, 2019, 156, S-50.	0.6	2
166	Defining Optimal Care for Functional Gut Disorders - Multi-Disciplinary Versus Standard Care: A Randomized Controlled Trial Protocol. Contemporary Clinical Trials, 2019, 84, 105828.	0.8	2
167	DOP81 Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohnâ€™s disease. Journal of Crohn's and Colitis, 2019, 13, S078-S079.	0.6	2
168	Letter: tofacitinib in biologicâ€experienced ulcerative colitisâ€”a singleâ€centre realâ€world experience in Australia. Alimentary Pharmacology and Therapeutics, 2021, 54, 532-533.	1.9	2
169	Pelvic floor behavioral treatment for fecal incontinence and constipation in quiescent inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2022, 57, 807-813.	0.6	2
170	Childhood antibiotics as a risk factor for Crohn's disease: The <scp>ENIGMA</scp> International Cohort Study. JGH Open, 0, , .	0.7	2
171	ANORECTAL PHYSIOLOGY AND PATHOLOGY. ANZ Journal of Surgery, 1991, 61, 832-838.	0.3	1
172	Reply. Gastroenterology, 2015, 148, 1475-1476.	0.6	1
173	Editorial: treating strictures in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 1312-1313.	1.9	1
174	OP019 In faecal microbiota transplantation (FMT) for ulcerative colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short-chain fatty acid production are associated with remission (FOCUS study). Journal of Crohn's and Colitis, 2018, 12, S013-S014.	0.6	1
175	P260 Point of Care Ultrasound (POCUS) when performed by gastroenterologists with 200 supervised scans is accurate and clinically useful for patients with Crohnâ€™s disease. Journal of Crohn's and Colitis, 2018, 12, S232-S232.	0.6	1
176	P849 Urease-positive proteobacteria in Crohnâ€™s disease identified by novel ex vivo mucosal microbe culture combined with metagenomic sequencing (MC-MGS): the ENIGMA study. Journal of Crohn's and Colitis, 2019, 13, S548-S549.	0.6	1
177	P834 Proteus is a key candidate in the pathogenesis of Crohnâ€™s disease: mucosa, stool genomics and functional analysis: the ENIGMA study. Journal of Crohn's and Colitis, 2019, 13, S541-S541.	0.6	1
178	Low failure to attend rates and increased clinic capacity with Telehealth: A highly effective outpatient model that should continue beyond the COVIDâ€19 pandemic. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1136-1137.	1.4	1
179	Sa513 FOOD AS A RISK FACTOR FOR THE DEVELOPMENT AND PERPETUATION OF CROHN'S DISEASE.AN INTERNATIONAL CASE-CONTROL STUDY OF FOOD AND FOOD ADDITIVE INTAKE FROM BIRTH TILL NOW. THE ENIGMA STUDY.. Gastroenterology, 2021, 160, S-530.	0.6	1
180	The role of psychosocial factors in functional gut disease. The European Journal of Surgery Supplement: = Acta Chirurgica Supplement, 1998, , 37-40.	0.2	1

#	Article	IF	Citations
181	Pharmacological treatment of irritable bowel syndrome--from concept to sales. The European Journal of Surgery Supplement: = Acta Chirurgica Supplement, 2002, , 10-5.	0.2	1
182	Rectal sensation, the rectoanal reflex, and faecal incontinence. International Journal of Colorectal Disease, 1988, 3, 232-233.	1.0	0
183	MMXTM mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases, 2008, 14, S24.	0.9	0
184	Steroid-Free remission in response to Adalimumab therapy over 2 years in patients with CrohnÊ¼s Disease: Results From open-label extension of the CHARM trial. Inflammatory Bowel Diseases, 2008, 14, S33.	0.9	0
185	Satisfaction with therapy among patients treated with MMXTM mesalamine for maintenance of remission in patients with mild-to-moderate ulcerative colitis. Inflammatory Bowel Diseases, 2008, 14, S24.	0.9	0
186	Adalimumab Therapy maintains meaningful rates of steroid-free remission in patients with CrohnÊ¼s Disease for up to 3 Years of Therapy: Results From an Open-Label Extension of CHARM. Inflammatory Bowel Diseases, 2009, 15, S41-S42.	0.9	0
187	PTH-034â€...Stress-induced immunomodulation in irritable bowel syndrome suppresses Th1 and Th2 cytokines. Gut, 2010, 59, A136.2-A136.	6.1	0
188	Reply. Gastroenterology, 2015, 148, 856-857.	0.6	0
189	Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab- authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 170-171.	1.9	0
190	Editorial: visceral fat as a predictor of postâ€operative recurrence of Crohn's diseaseâ€"Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1552-1553.	1.9	0
191	P589 Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. Journal of Crohn's and Colitis, 2017, 11, S380-S381.	0.6	0
192	P575 Simple novel tacrolimus enemas are very effective in severe refractory proctitis. Journal of Crohn's and Colitis, 2019, 13, S402-S402.	0.6	0
193	P195 MRI is predictive of, and anti-TNF treatment changes, the clinical course of Crohn's disease strictures. Journal of Crohn's and Colitis, 2019, 13, S188-S188.	0.6	0
194	P852 Characterisation of Crohnâ€™s disease mucosa-associated microbiota by a novel combination of microbe culture and metagenomic sequencing (MC-MGS): the ENIGMA study. Journal of Crohn's and Colitis, 2019, 13, S550-S550.	0.6	0
195	Approach to Dietary Restriction in Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
196	Intestine mucosal ILâ€22 is reduced following oral probiotic administration: implications on epithelial barrier repair. FASEB Journal, 2013, 27, 944.2.	0.2	0
197	P449 Autologous fat graft injection for the treatment of perianal fistulas in Crohnâ€™s disease: A systematic review and single-arm meta-analysis. Journal of Crohn's and Colitis, 2022, 16, i428-i429.	0.6	0